Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-Defining Study of a NAT2 Phenotype-Based Dosing Regimen of Intravenous Amonafide L-Malate Administered Weekly in Men With Androgen-Independent Prostate Cancer (AIPC)

NCT00087854 is registered in ClinicalTrials.gov with Xanthus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00087854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00087854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-Defining Study of a NAT2 Phenotype-Based Dosing Regimen of Intravenous Amonafide L-Malate Administered Weekly in Men With Androgen-Independent Prostate Cancer (AIPC)
Lead sponsor
Xanthus Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2004
Completion date
December 31, 2005
Enrollment
40
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer